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ttp://dx.doi.org/10.1016/j.ajpath.2013.03.021Colorectal cancer is the second leading cause of death from cancer. Osteopontin (OPN) is a component of
tumor extracellular matrix identiﬁed as a key marker of cancer progression. The estrogen-related receptor
a (ERRa) has been implicated in endocrine-related cancer development and progression, possibly through
modulation of cellular energy metabolism. Previous reports that ERRa regulates OPN expression in bone
prompted us to investigate whether ERRa controls OPN expression in human colorectal cancer. Using a tissue
microarray containing 83 tumor-normal tissue pairs of colorectal cancer samples, we found that tumor
epithelial cells displayed higher staining for ERRa than normal mucosa, in correlation with elevated OPN
expression. In addition, knocking down endogenous ERRa led to reduced OPN expression in HT29 colon
cancer cells. Promoter analysis, inhibition of ERRa activity, and expression and mutation of potential ERRa
response elements in the proximal promoter of human OPN showed that ERRa and its obligate co-activator,
peroxisome proliferator-activated receptor g co-activator-1 a, positively control human OPN promoter
activity. Furthermore, chromatin immunoprecipitation experiments conﬁrmed in vivo occupancy of the OPN
promoter by ERRa in HT29 cells, suggesting that OPN is a direct target of ERRa in colorectal cancer. These
ﬁndings suggest an additionalmechanismbywhich ERRaparticipates in the development and progression of
colorectal cancer, further supporting the relevance of targeting ERRawith antagonists as anticancer agents.
(Am J Pathol 2013, 183: 266e276; http://dx.doi.org/10.1016/j.ajpath.2013.03.021)Supported by the Canadian Institutes for Health Research (CIHR) grants
MOP-97836 (J.F.B.) and MOP-89970 (J.C.C.). The CRC biobank was
supported by CIHR team grant CTP-82942.
All authors are part of the Canadian Institutes for Health Research Team
on the Digestive Epithelium. J.F.B. and J.C.C. are members of the Fonds de
la Recherche du Québec - Santé (FRQS) funded Centre de Recherche
Clinique Étienne-Le Bel. J.F.B. holds the Canada Research Chair in
Intestinal Physiopathology. J.C.C. was a scholar from the FRQS.Despite advanced early diagnosis and clinical treatment,
colorectal cancer (CRC) remains a worldwide health
concern. More than 608,700 deaths were estimated to occur
in 2008 from CRC,1 representing the fourth leading cause of
death after lung, stomach, and liver cancers. CRC devel-
opment and progression are complex events that involve
multistep accumulations of numerous genetic mutations and
epigenetic events that result in unregulated transcription of
genes involved in cancer cell growth and in alterations in
growth factor-regulated signaling pathways.
Osteopontin (OPN) is a secreted matricellular glyco-
phosphoprotein produced by osteoblasts and osteoclasts which
plays an important role in bonemineral deposit.2 OPN has alsostigative Pathology.
.been found to be expressed in various cell types, therefore
contributing to numerous physiological processes and to the
pathogenesis of a variety of disease states, including chronic
inﬂammation and cancer.3 OPN is involved in almost all steps
of tumor progression by regulating cellematrix interactions
ERRa and Osteopontin Expression in CRCand cell signaling through binding with integrins and CD44
receptors.4 In particular, OPN has been reported to promote
metastasis by increasing tumor growth, cell migration, degra-
dation of the extracellular matrix, cell survival in blood stream,
and angiogenesis (reviewed in Wai and Kuo5). OPN is over-
expressed in a number of cancers, including CRC in which it
has been identiﬁed as one of the leading markers in cancer
progression.6e9 Of note, OPN can be expressed by both cancer
cells and cellular components of the tumor’s microenviron-
ment.10 Nevertheless, in microdissected intestinal adenomas
from APCMin/þ mouse, the observed increase in OPN gene
expression has been shown to be of epithelial origin,11 sug-
gesting thatOPN is a transcriptional target of factors implicated
in epithelial carcinogenesis. Of these, it has been reported that
activated RAS12 and mutant p5313,14 can induce OPN expres-
sion. Furthermore, in silico analysis of the OPN proximal
promoter aswell as experimental evidences suggest thatmurine
and human OPN gene expressions are regulated by numerous
factors, including Sp1, AP-1, c-jun,myc, PEA3, and other ETS
family members, SMAD, estrogen receptor a, Nurr1 nuclear
receptor, and the Wnt/b-catenin/T-cell factor pathway.15e21
OPN regulation also depends on a number of transcription
factors relevant to bone biology, including estrogen-related
receptor a (ERRa), for which the contribution to bone for-
mation has been widely studied in the past years.22e24 Despite
its structural similarity with estrogen receptors, ERRa is an
orphanmember of the nuclear receptor superfamily because it is
not activated by estrogen-like molecules.25 The activity of
ERRa is rather controlled by the interaction with master regu-
lators of energy metabolism such as peroxisome proliferator-
activated receptor g co-activator 1 a/b (PGC-1a/b), which
are considered as protein ligands of ERRa.26,27 Although no
synthetic ERRa agonist has been reported to date, selective
ERRa antagonists, including XCT790, have been useful to
delineate ERRa functions in vitro.28,29 ERRa is a regulator of
metabolic function that controls multiple biosynthetic path-
ways involved in energy metabolism.30 In addition, growing
evidences support the role of ERRa as a protumorigenic factor.
For instance, ERRa is overexpressed and correlates with
unfavorable biomarkers and poor clinical outcome in various
cancer cell types, including breast,31e34 prostate,35,36 ovarian,37
endometrium38 and colorectal.39 Moreover, in CRC, semi-
quantitative real-time PCR determination revealed slightly
higher ERRa expression in tumors than in matched normal
mucosa.40 In support of its oncogenic action, ERRa has also
been reported to participate in breast cancer cell proliferation
and migration as well as in vascular endothelial growth factor-
induced tumor angiogenesis.34,41e44 Although the contribution
of ERRa as a transcriptional regulator of energy metabolism is
well established, a subset of ERRa targets has also been shown
to be highly relevant to tumor biology.42,45 This suggests that
ERRa targets key hallmarks of cancer and thus could represent
a candidate for the development of new cancer therapeutic
agents.
In the light of these ﬁndings, we investigated whether
ERRa protein expression is induced in colon cancer epithelialThe American Journal of Pathology - ajp.amjpathol.orgcells and whether ERRa is a transcriptional regulator of
human OPN expression.
Materials and Methods
Human Tissues
Samples of 83 CRC and paired normal tissues (at least 10 cm
from the tumor) were obtained from patients undergoing
surgical resection without prior neoadjuvant therapy.
Tissues were obtained after patients’ written informed
consent, according to a protocol approved by the Institu-
tional Human Subject Review Board of the Centre Hos-
pitalier Universitaire de Sherbrooke. Samples were ﬁxed
with 4% paraformaldehyde in 0.1 mol/L PBS at 4C
overnight, dehydrated in graded alcohols, and embedded in
parafﬁn. Patient samples were histologically classiﬁed and
graded according to World Health Organization guidelines
and tumor-node-metastasis staging criteria. Furthermore,
genomic DNA of tumor cells was extracted from 10-mm
thick sections of formalin-ﬁxed parafﬁn-embedded tissue
with the use of a FFPE DNA Isolation Kit for Cells and
Tissues (Qiagen, Valencia, CA) and ampliﬁed by PCR.
Presence of mutations in tumor samples was detected by
direct sequencing in 81 patients (Plateforme de Séquen-
çage et de Génotypage des Génomes du Centre de
Recherchée du Centre Hospitalier de l’Université Laval,
Quebec City, QC, Canada). Molecular characterization
included microsatellite instability status (MSI panel
marker; NCI, Bethesda, MD), mutation status of p53
(exons 5 to 8 containing mutation hotspots), oncogenic
KRAS (alias Ki-ras; codons 12, 13, and 61), and
BRAF(V600E) mutations, inactivating mutations of APC
(mutation cluster region) and activating mutations of
CTNNB1 (exon 3). Clinicopathological and molecular
characteristics of the series are described in Table 1.
TMA Construction
Tissue microarray (TMA) was performed as previously
described.46 Brieﬂy, serial sections were processed for
routine hematoxylin and eosin staining to identify tumor and
normal mucosal tissue to be punched. Thereafter, tissue
cores with a diameter of 2 mm were removed from ﬁxed
parafﬁn-embedded tissue blocks, using a dermatological
biopsy punch (Miltex Inc., York, PA), arrayed on a recipient
parafﬁn block, covered with hot parafﬁn, and cooled down
at 4C for 1 hour to create a new block. From the new
TMA block, 4-mm thick sections were mounted on charged
glass slides and stored at room temperature.
Immunohistochemistry
Parafﬁn-embedded sections were deparafﬁnized in xylene.
Antigen retrieval was performed in citrate buffer (pH 6).
Endogenous peroxidases were quenched with 0.3% H2O2.267
Table 1 Clinicopathological Parameters and Molecular Charac-
teristics of Patients in This Series of CRC Samples
Parameter Value
Age, median (range) (years) 69 (61-78.8)
Sex
Male, no. (%) 48 (57.8)
Female, no. (%) 35 (42.2)
Tumor localization
Left þ rectum, no. (%) 28 (33.7)
Right þ transverse, no. (%) 55 (66.3)
Tumor grade
1, no. (%) 0 (0)
2, no. (%) 50 (60.2)
3, no. (%) 25 (30.1)
4, no. (%) 8 (9.6)
Tumor stage (TNM)
1, no. (%) 8 (9.6)
2, no. (%) 28 (33.7)
3, no. (%) 33 (39.8)
4, no. (%) 14 (16.9)
Microsatellite instability
MSS, no. (%) 63 (75.9)
MSI, no. (%) 18 (21.7)
APC/CTNNB1
No mutation, no. (%) 48 (57.8)
Mutation, no. (%) 33 (39.8)
KRAS/BRAF
No mutation, no. (%) 46 (55.4)
Oncogenic mutation, no. (%) 35 (42.2)
p53
No mutation, no. (%) 48 (60.2)
Mutation, no. (%) 33 (37.3)
MSI, microsatellite instability; MSS, microsatellite stable; TNM, tumor-
node-metastasis.
Boudjadi et alTissues were treated with streptavidin/biotin blocking
reagent (Vector Laboratories Inc., Burlingame, CA) and
blocking serum [PBS 1X, 0.1% BSA, 0.2% Triton X-100,
0.1% donkey serum, 0,1% goat serum (all from Sigma-
Aldrich, Oakville, ON, Canada)]. Sections were incubated
with anti-OPN (1:200; R&D Systems, Minneapolis, MN)
and anti-ERRa (1:100; NLS5402; Novus Biologicals, Lit-
tleton, CO) overnight at 4C and with the corresponding
biotinylated goat (Millipore, Bedford, MA) and rabbit
(GE Healthcare, Baie d’Urfé, QC, Canada) secondary anti-
bodies for 1 hour at room temperature. Slides were incu-
bated with horseradish peroxidase-streptavidin and stained
with 3,30-diaminobenzidine (Vector Laboratories Inc.), then
counterstained with light hematoxylin, dehydrated, and
protected with a coverslip. Representative images were
acquired with a Leitz Orthoplan microscope (Leica, Wet-
zlar, Germany).
Expression Analysis
The scoring system for protein expression in tumor and
normal samples was based on staining intensity (no
staining Z 1; weak staining Z 2; moderate staining Z 3;268strong staining Z 4) and percentage of expression in
epithelial cells (0% to 25%Z 1; 25% to 50%Z 2; 50% to
75%Z 3; 75% to 100%Z 4). Final immunostaining score
(intensity  percentage of expression) ranged from 1 to 16.
The expression index for each patient was deﬁned as the
difference between the expression score for tumor and
normal paired samples: no change (0), increased expression
in cancer (positive indexZ 1), and decreased expression in
cancer (negative indexZ 1).
Cell Culture and Treatment Conditions
The human transformed embryonic kidney cells (HEK293T)
and the human colon carcinoma cell line HT29 were origi-
nally obtained from the American Type Culture Collection
(Manassas, VA). The HT29 cell line was selected because of
its high ERRa and OPN expression. Cells were cultured in
Dulbecco’s modiﬁed Eagle’s medium (Invitrogen, Burling-
ton, ON, Canada) supplemented with 10% fetal bovine
serum, 2 mmol/L glutamine, 10 mmol/L HEPES, 100 U/mL
penicillin, and 100 mg/mL streptomycin (Wisent, St-Bruno,
QC, Canada) and maintained in a 5% CO2-humidiﬁed
atmosphere at 37C. Cells were also incubated with the
selective ERRa inverse agonist XCT790 for 48 hours at
5 mmol/L (Sigma-Aldrich), known to reduce ERRa activity
and to increase its degradation.28
Lentivirus-Mediated RNA Interference
The PLK0.1 lentiviral shRNA expression vector targeting
hERRa (NM_004451) and control scrambled (shCTL) were
obtained from Sigma-Aldrich. Lentiviruses were produced
by cotransfecting the shRNA expression vector and the Vira
Power Lentiviral Packaging Mix (Invitrogen) in HEK293T
cells. HT29 cells were infected with viral suspension for
2 days and maintained in medium supplemented with 5 mg/
mL puromycin (Sigma-Aldrich).
RNA Extraction and Quantitative Real-Time RT-PCR
Analysis
Total RNA was isolated with the Totally RNA kit (Invi-
trogen) according to the manufacturer’s instructions. RNA
was reverse-transcribed with AMV RT (Roche Diagnostics,
Laval, QC, Canada), and cDNA samples were ampliﬁed
with the following primer pairs: OPN forward, 50-TTGC-
AGTGATTTGCTTTTGC-30, and reverse, 50-GTCATGG-
CTTTCGTTGGACT-30; ERRa forward, 50-CGAGAGG-
AGTATGTTCTA-30, and reverse, 50-CCCGCCCGCCG-
CCGCTCAGCA-30; human acidic ribosomal phosphopro-
tein P0 (RPLPO) forward, 50-GCAATGTTGCCAGTG-
TCTG-30, and reverse, 50-GCCTTGACCTTTTCAGCA-
CAA-30. Quantitative real-time PCRs were performed in
triplicate with the use of Brilliant II SYBR Green QPCR
master mix in a MX3000P Real-Time System (Stratagene,
Cedar Creek, TX). Thereafter, mRNA expression levelsajp.amjpathol.org - The American Journal of Pathology
Figure 1 ERRa andOPN expression scores are higher in CRC than in paired
normal tissues. Distribution of immunostaining scores for ERRa (A) and
OPN (B) in normal margin tissues and CRC tissues. Boxes represent lower
quartile,median, andupper quartile, whereaswhiskers represent the lowest and
highest immunostaining scores. ERRa and OPN expressions are signiﬁcantly
higher in CRCs than in normal paired tissues. ***P < 0.001, Wilcoxon test.
ERRa and Osteopontin Expression in CRCwere calculated with the DDCT method,
47 normalized to
RPLPO expression and expressed as fold difference relative
to that of negative control cells (shCTL).
Protein Expression and Immunoblotting
Cells were lyzed in chilled Triton buffer (50 mmol/L Tris-
HCl, pH 7.5, 1% Triton X-100, 100 mmol/L NaCl, 5 mmol/L
EDTA) supplemented with protease inhibitors. Fifty-
microgram proteins were subjected to electrophoresis on
10% SDS-PAGE gel and transferred onto polyvinylidene
diﬂuoride membrane (GE Healthcare). Membranes were
incubated overnight at 4C with primary antibodies, followed
by incubation with horseradish peroxidase-coupled secondary
antibodies. Detection was performed with the Pierce ECL
Western Blotting Substrate (Pierce, Rockford, IL). Anti-
bodies used were anti-hERRa NLS5402 (1/2000; Novus
Biologicals); anti-OPN AF1433 (1/2000; R&D Systems), and
anti-actin MAB1501R (1/5000; Chemicon International,
Billerica, MA). Secondary antibodies were anti-rabbit IgG
horseradish peroxidase and anti-mouse IgG horseradish
peroxidase (1/5000; GE Healthcare).
OPN Promoter Analysis and Site-Directed Mutagenesis
The human OPN promoter sequence was analyzed for
ERRa response elements (ERREs) with the use of the
MatInspector version 2.7 web-based search algorithm from
Genomatix Software (Munich, Germany). A 1-kb OPN
human promoter inserted in the pSGG plasmid vector was
purchased (Switch Gear Genomics, Menlo Park, CA) and
named OPN-luc. Mutations of ERRE-S1, ERRE-S2, ERRE-
S3, and ERRE-S1 þ ERRE-S2 potential ERRa response
elements were introduced with the use of the Geneart Site-
Directed Mutagenesis System according to the manufacturer’s
instructions (Invitrogen). Pairs of oligonucleotide primers
used were ERRE-S1 forward, 50-CCCTCAAAAACCCC-
ACCATTTGGGTAATAGTATTGCATT-30, and reverse,
50-AATGCAATACTATTACCCAAATGGTGGGGTTTT-
TGAGGG-30; ERRE-S2 forward, 50-30, and reverse, 50-
TCCGCTGTGTCACTGCAAATATGTGCAACCTTGG-
GC-30; ERRE-S3 forward, 50-AAAGCTAAGCTTGAGT-
AGTAGACCAGTGAGGCAAGTTTTCTG-30, and reverse,
50-CAGAAAACTTGCCTCCATGGTCTACTACTCAAGC-
TTAGCTTT-30. The integrity of each construct was con-
ﬁrmed by sequencing.
Plasmids and Cell Transfections
HEK293T cells were transfected with Lipofectamine 2000
(Invitrogen) according to the manufacturer’s protocol. Cells
were plated in 12-well plates and transfected in triplicates
24 hours later with the following amounts of plasmid
DNAs: 100 ng of pSGG OPN-luciferase or mutated pSGG
OPN-luciferase reporters, 200 ng of plenti hERRa, 200 ng
of plenti HA-hPGC1a, and 2 ng of pRL-SV40 renillaThe American Journal of Pathology - ajp.amjpathol.orgluciferase vector. In some experiments, 200 ng of PLK0.1
shCTR versus 200 ng of PLK0.1 shERRa were transfected
together with expressing vectors, and 5 mmol/L XCT790
versus dimethyl sulfoxide was added to the medium
concomitantly with cell transfections. Transfections were
allowed to proceed for 3 hours at 37C, followed by
replacement with Dulbecco’s modiﬁed Eagle’s medium
10% fetal bovine serum media. Cells were incubated an
additional 48 hours before assaying for luciferase activities,
using a dual luciferase assay kit (Promega, Madison, WI).
All results represent experiments conducted at least three
times.
ChIP Assay
Chromatin immunoprecipitation (ChIP) assay was performed
on HT29 cells as previously described.48 Brieﬂy, after soni-
cation, soluble chromatin fragments of 500 to 1000 bp in
length were incubated with 5 mg of anti-hERRa antibody,
rabbit anti-IgG antibody, or no antibody for 16 hours at 4C,
followed by incubation with 40 mg of salmon sperm DNA/
protein A-agarose for 1 hour at 4C. Immunoprecipitates269
Boudjadi et alwere washed and eluted as previously described.48 Samples
were then treated with RNase A (Roche Diagnostics) for
30 minutes at 37C and with proteinase K (Roche Diagnos-
tics) for 2 hours at 42C. Isolated DNA fragments were
puriﬁed with QIAquick spin kit (Qiagen), and quantitative
PCRs were performed. A region located between 784 and
593 bp upstream of OPN initiation start site was ampliﬁed
with the following primer pair: forward 50-CGCAGAC-
GATTTGCATCTAA-30 and reverse 50-GTGGTTCTGAA-
TTCCGCTGT-30. Enrichment for this region was normalized
against a negative control segment, and enrichment of the
ERRa promoter region was used as positive control, as
previously described.48
Statistical Analysis
Statistical analysis was performed with SPSS software
version 18.0 (SPSS Inc., Chicago, IL) and StatXact software
version 6 (Cytel Software Corporation, Cambridge, MA).
Comparisons between groups were performed with one-way
analysis of variance, with Bonferroni correction for multiple
comparisons. A nonparametric Wilcoxon test was used toFigure 2 Representative co-increased expressions of (ERRa and OPN immun
(normal) tissue from four patient samples (patient numbers: 4, 66, 57, and 64). Co
tissues stained with anti-ERRa antibody. Column 3: Cancer tissues stained with an
The identiﬁcation number of representative patients is indicated on the left. Scale
and OPN immunostaining.
270compare scores between tumor and normal samples for each
marker. The weighted k was calculated for correlation
analysis between each marker. Fisher’s exact test was used
to study the statistical association between clinicopatho-
logical parameters and the expression index for ERRa and
OPN. Data were expressed as the means  SE of at least
three different experiments. Statistically signiﬁcant differ-
ences were deﬁned as P < 0.05.
Results
ERRa and OPN Expression Are Co-Overexpressed in
Human CRC Samples
To evaluate the expression of ERRa and OPN at the protein
level in our tissue collection, we constructed a TMA that
contained one spot of normal mucosa and one spot of CRC
for 83 patients, in which the mutation in key genes involved
in colorectal carcinogenesis were characterized (Table 1).
ERRa was found to be expressed in the epithelium of most
CRC samples, the expression score being signiﬁcantly
higher in cancerous tissues than inmargin tissues (medianZ 9ohistochemical staining in tumoral compared with adjacent nonmalignant
lumn 1: Cancer tissues stained with anti-ERRa antibody. Column 2: Normal
ti-OPN antibody. Column 4: Normal tissues stained with anti-OPN antibody.
bars: 50 mm (columns 1e4). TMA sections were used for subsequent ERRa
ajp.amjpathol.org - The American Journal of Pathology
Table 2 ERRa and OPN Expressions Are Correlated in Colorectal
Cancer and Paired Normal Tissues
OPN index
Total1 0 1
ERRa index 1 3* 1 4 8
0 3 10* 8 21
1 4 13 37* 54
Total 10 24 49 83
Correlation table for ERRa and OPN immunohistochemical expression
indices in cancer relative to nontumor tissue (index: 0Z no change; 1Z
increased in cancer; 1Z decreased in cancer). ERRa and OPN expressions
were higher in 65% (54 cases) and 59% (49 cases) of tumors compared with
paired normal tissues, respectively. The relative expressions of both proteins
were signiﬁcantly concordant in 60.24% of cases (k Z 0.27, P Z 0.01).
ERRa and OPN both increased in 44.57% of tumors studied (37 cases).
*The number of cases in which ERRa and OPN indices are correlated with
each other.
Figure 3 Silencing ERRa down-regulates OPN expression in HT29 colon
cancer cells. HT29 cells were infected with lentivirus encoding for a non-
targeting shRNA (shCTL) or shRNA targeting ERRa (shERRa) A: After 4 days,
ERRa and OPN gene expression was measured by quantitative real-time PCR
and normalized to RPLPO expression. Data are presented as the means  SD
expression, relative to shCTL-treated cells, from three experiments per-
formed in triplicate. *P < 0.05, ***P < 0.001. Numbers are exact
expression ratio. B: HT29 cells were lyzed 4 and 12 days after infection, and
ERRa and OPN expression were assayed by Western blot analysis and
normalized to actin expression.
ERRa and Osteopontin Expression in CRCand 6, respectively; P< 0.001, Wilcoxon test) (Figure 1A). In
a paired comparison, immunostaining scores for ERRa
expression were observed to be higher in cancerous than in
noncancerous tissues in 54 patients (65.1%), equal in
21 patients, and lower in only 8 patients. Interestingly, ERRa
expression was also observed in the cytoplasm from
samples with strong epithelial nuclear ERRa expression
(Figure 2). Although not as strong as epithelial cells, ﬁbro-
blasts, endothelial cells, and lymphocytes within the tumor
microenvironment displayed noticeable ERRa immunostain-
ing (Figure 2). As a second protein of interest, only few CRC
displayed no OPN immunostaining in epithelial cells (four
samples), and expression scores were signiﬁcantly higher in
cancerous tissues than in normal colon (median Z 6 and 4,
respectively; P< 0.001, Wilcoxon test) (Figure 1B). In the 83
matched samples assessed, staining scores for epithelial OPN
were higher in cancerous than in noncancerous tissues in
49 patients (59.02%), equal in 24 patients, and lower in only
10 patients. Although not scored, variable OPN immuno-
staining in endothelial and mesenchymal cells were observed
from normal and cancerous tissues, being in some samples
either stronger or weaker than in epithelial cells (Figure 2).
Expression indices for ERRa and OPN immunostaining did
not correlate with clinicopathological ormolecular parameters,
including tumor grade and stage as well as microsatellite
instability and mutations in APC/CTNNB1, RAS/RAF, and
p53. Of particular interest, scores for ERRa and OPN immu-
nostainingwere signiﬁcantly correlated in 60.24% of tissues in
this series (weighted kZ 0.27, PZ 0.014), and both proteins
were coeup-regulated in 44.57% of tumors relative to adja-
cent normal tissues (Table 2).
ERRa Regulates OPN Expression in HT29 Colon Cancer
Cells
To investigate whether OPN expression is regulated by
ERRa in colon cancer cells, its endogenous expression wasThe American Journal of Pathology - ajp.amjpathol.orgsilenced in HT29 cells, using a lentivirus-based shRNA
strategy. Figure 3 shows that speciﬁc shRNAs (shERRa)
efﬁciently knocked down ERRa mRNA and protein
expression, compared with HT29 cells infected with shCTR.
Silencing ERRa during 4 days resulted in a marked
reduction in OPN gene and protein expression (Figure 3, A
and B) which persisted up to 12 days after infection of
HT29 cells (Figure 3B). These ﬁndings support a positive
contribution of ERRa to the expression of OPN in colon
cancer cells.OPN Is a Direct Target of ERRa
In view of reports that ERRa controls the murine OPN
promoter in osteoblastic cells through either a derivative of
an ERRa response element23 or a noncanonical response
element,24 we next analyzed the human OPN promoter
sequence in silico to detect potential ERRE composed of the
extended ERE half-site AGGTCA (or its reverse comple-
ment). Three potential ERRa response elements were found
located within the proximal promoter of hOPN: ERRE-S1,
GACCTAGG located at 705 to 696 bp; ERRE-S2,271
Figure 4 ERRa, co-activated by PGC1a, induces hOPN promoter
activity. A: HEK293T cells were transiently transfected with 100 ng of
hOPN-Luc reporter and with 200 ng of ERRa and/or PGC1a expression
vector. Two ng per well of pRL-SV40 renilla luciferase reporter was used as
an internal control in 12-well plates. Promoter-dependent luciferase
activities were determined as fold activation over the individual luciferase
activity with PV alone. Results are represented as the means  SEM from
three independent experiments, each performed in triplicate. ***P <
0.0001 (one-way analysis of variance). B: OPN luciferase assay in HEK293T
cells cotransfected with 200 ng of ERRa and PGC1a expression vector,
together with plasmid vector containing shERRa DNA sequence targeting
ERRa or shCTR. C: OPN luciferase assay in HEK293T cells cotransfected with
200 ng of ERRa and PGC1a expression vector and treated with 5 mmol/L
XCT790 or DMSO as control for 48 hours. **P < 0.001, t-test (B and C).
DMSO, dimethyl sulfoxide; PV, Plenti vector.
Boudjadi et alCACAGGTCA, located at 630 to 621; and ERRE-S3,
TAAAGGACA, located at 400 to 391 bp from the
transcription initiation site. As a ﬁrst step in evaluating the
signiﬁcance of these imperfect sites, the human proximal
1-kb OPN region cloned in front of a luciferase reporter
gene was studied. The binding capacity of ERRa to this
region was characterized by transient cotransfection in
HEK293 cells, using PGC1a as putative ERRa co-activator.
As previously reported, ERRa was a weak activator, and its
overexpression did not signiﬁcantly affect hOPN promoter-
dependent luciferase activity (Figure 4A). In contrast,
PGC1a transfection led to a moderate induction of lu-
ciferase activity (Figure 4A), possibly via co-activation
of endogenous ERRa in HEK293T cells. Furthermore,
co-expression of PGC1a and ERRa strongly induced hOPN
promoter activity over luciferase activity with vector alone.
Of note, cotransfection of increasing doses of PGC1a and
ERRa resulted in synergistic activation of the hOPN
promoter (data not shown). To test whether ERRa is
required for PGC1a-mediated hOPN promoter induction,272transiently transfected cells were incubated with shERRa
and with the ERRa inverse agonist XCT790. As shown in
Figure 4B, silencing or inhibiting ERRa activity and
expression resulted in substantial drops in PGC1a/ERRa-
induced hOPN promoter activity (by 55% and 62%,
respectively).
Because three imperfect ERRa response elements could
be found in the proximal hOPN promoter region, we next
sought to map in further detail the region required for
ERRa control of hOPN expression. We therefore per-
formed mutation analysis of the hOPN-Luc reporter in
HEK293T cells. As shown in Figure 5, A and B, disruption
of ERRE-S1 led to 68.3% reduction of the hOPN pro-
moter activity induced by ERRa þ PGC1a, relative to the
wild-type hOPN promoter. Interestingly, hOPN reporter
constructs harboring mutation in either ERRE-S2 or
ERRE-S1 þ ERRE-2 sequences displayed markedly
reduced basal and ERRa þ PGC1a-induced luciferase
activity (Figure 5, C and D). These ﬁndings suggest that
ERRa, co-activated by PGC1a, is able to control hOPN
through the ERRE-S1 and/or the ERRE-S2 sites. Further-
more, the ERRE-S2 site may be more functional than the
ERRE-S1 site because its disruption impaired basal hOPN
activity, whereas mutation in the ERRE-S1 sequence did
not further affect the drop in luciferase activity observed in
ERRE-S2emutated reporter. In contrast, mutating the
ERRE-S3 sequence did not affect basal or induced lucif-
erase activity, suggesting that this potential binding site is
not a functional ERRE (Figure 5E). Interestingly, ERRa
could also modulate hOPN promoter activity through a
noncanonical element because disruption of the ERRE-S1
and ERRE-S2 site did not completely abolish ERRa þ
PGC1a-induced luciferase activity. Taken together, these
results suggest that ERRa, co-activated by PGC1a, posi-
tively regulates the activity of the human OPN proximal
promoter.In Vivo Occupancy of the Human OPN Promoter with
ERRa in Colon Cancer Cells
After showing that the ERRE-S1 and ERRE-S2 sites are
critical for ERRa responsiveness in hOPN and that ERRa
modulates OPN expression in HT29 colon cancer cells, we
next performed a ChIP assay to test whether ERRa binds to
the hOPN promoter in the native chromatin environment of
HT29 colon cancer cells. As shown in Figure 6, ChIP with
a human ERRa-speciﬁc antibody resulted in a signiﬁcant
enrichment in the genomic fragment that contained the
ERRE-S1 and ERRE-S2 sites in the hOPN promoter (2.88-
fold). As a strong positive control, we found endogenous
ERRa to be tethered to autoregulation sites within the
promoter of the human ERRa gene (11.34-fold enrichment).
As negative control, weak precipitation was detected with
the use of no antibody or anti-rabbit IgG. Together, these
data suggest that ERRa binds to the cis-regulatory domainajp.amjpathol.org - The American Journal of Pathology
Figure 5 Mutation analysis of potential ERREs in the hOPN promoter. The functionality of three potential ERREs was determined by mutation analysis. A:
Luciferase assay in HEK293T cells with the use of wild-type hOPN-luc reporter. BeE: ERRE-S1, ERRE-S2, ERRE-S1 þ ERRE-S2, and ERRE-S3 mutated reporters,
respectively. Underlined letters are components of the putative ERRa response element (TNAAGGTCA, in which N can be any base) and mutated nucleotides
are labeled as white letters in gray frames. The ﬁve reporters (100 ng) were cotransfected with 200 ng of ERRa and/or PGC1a expression vector. Two ngs per
well of pRL-SV40 renilla luciferase reporter was used as an internal control in 12-well plates. Promoter-dependent luciferase activities were determined as fold
activation over the individual luciferase activity with vector alone in wild-type hOPN-luc reporter (top column in A). The means  SD of three experiments
performed in triplicate wells are shown. PV, Plenti vector.
ERRa and Osteopontin Expression in CRCof the endogenous OPN promoter in HT29 and trans-
activates this gene.
Discussion
In the present study, we demonstrated that the immunohis-
tochemical expression of the nuclear receptor ERRa is
elevated in neoplastic epithelial cells of a large subset of
CRC samples, in correlation with higher OPN expression in
tumors versus normal mucosa. Furthermore, we showed
with the use of loss-of-function approaches that ERRa
contributes to OPN expression in HT29 colon cancer cells.
Results from the functional and mutation analysis of the
OPN promoter and ChIP assay also suggest that OPN is
a direct target gene of ERRa in colon cancer cells.
ERRa shares considerable structural similarity with ERa,
and reports of functional cross talk between these nuclear
receptors prompted the ﬁrst investigations of ERRa
expression in hormone-responsive cancers. Indeed, ERRa
is overexpressed in several cancer types, and elevated
expression has been correlated with poor clinical outcome
in breast and ovarian cancers.31,32,37 Furthermore, ERRa
gene expression has been determined by semiquantitative
real-time PCR in CRCs and found to be modestly but
signiﬁcantly higher in tumors than in matched normal
mucosa and to correlate with higher histological grade and
tumor-node-metastasis stage of CRC.39 In the present study,The American Journal of Pathology - ajp.amjpathol.orgwe constructed a tissue microarray with 83 tumor-normal
tissue pairs from patients with CRC and analyzed the
samples by ERRa immunostaining. This powerful approach
allows the simultaneous analysis of tens of samples, and its
use to validate transcriptomic analysis is rapidly growing. In
agreement with previously reported ERRa gene expression
analysis, we ﬁrst observed that scores for ERRa expression
were signiﬁcantly higher in tumors than in normal tissues.
Although our analysis focused on epithelial cells, the
examination of the tumor microenvironment revealed ERRa
immunostaining in ﬁbroblasts, endothelial cells, and
lymphocytes. This is consistent with known functions of
ERRa in immunity via reactive oxygen species production
in macrophages and T-cell activation and differentia-
tion.49,50 Although ERRa is mostly located in the nucleus,
noticeable cytoplasmic staining was also observed in tumor
cells with high nuclear ERRa expression. As recently
proposed, this could involve a feedback loop in which
activated ERK8 inhibits ERRa and promotes its nuclear
exclusion in cancer cells.51 Interestingly, we did not observe
any correlation between ERRa expression index and clini-
copathological parameters, including tumor stages and
grades. Further investigation in a larger set of CRC samples
would be needed to test any association between ERRa
overexpression and oncogenic pathways.
OPN has been considered an important determinant in
bone formation and tumor progression. In keeping with273
Figure 6 ERRa occupies the hOPN promoter in HT29 colon cancer cells.
ChIP assay with a human ERRa-speciﬁc antibody (black columns) was
performed in HT29 cells. Mock immunoprecipitations with the use of rabbit
anti-IgG (white columns) and without the use of antibody (gray columns)
were performed as negative control. Data were calculated with PCR quan-
tiﬁcation of DNA fragments located between 784 and 593 bp upstream
of the OPN initiation start site relative to a negative control DNA fragment.
Enrichment for the autoregulation sites within the promoter of the human
ERRa gene was used as a positive control. Results represent the mean of
three independent experiments, with real-time quantitative PCR performed
in triplicate. *P < 0.05, **P < 0.01 compared with negative control ChIP
(t-test). Ab, antibody.
Boudjadi et alpreviously reported analyses in whole colorectal tumor
mass,7e9,14 a statistically signiﬁcant increase in epithelial
OPN expression was detected in tumors herein compared
with normal mucosa. Our data did not ﬁnd any correlation
between OPN immunostaining index and either clinico-
pathological parameters or oncogenic molecular alterations.
Of note, OPN expression signiﬁcantly correlated with
ERRa expression, being co-overexpressed in 44.57% of
paired tumors. Taken together, these results suggest that
ERRa and OPN could participate in CRC biology and that
either the expression of the two proteins is positively
regulated by common oncogenic factors or OPN is a target
of ERRa in CRC.
Increasing evidences also support a role for ERRa as
a protumorigenic factor, possibly by contributing to the
coordination of energy-generating and biosynthetic pathways
to effectively promote cancer cell growth. In addition, func-
tional and physiological genomic approaches have found
that the ERRa/PGC-1 complex can positively regulate the
expression of a subset of genes which are key to tumor
biology. Interestingly, silencing ERRa in colon cancer cells
signiﬁcantly affects many biological gene cluster processes,
including biological adhesion gene ontology, together with
reduced cell proliferation, anchorage-independent cell growth,
and tumorigenicity in nude mice.52 Taking into consideration
the known role of ERRa in bone physiology and the co-
induction of ERRa and OPN in CRC samples, we postu-
lated that ERRa contributes to OPN expression in HT29 colon274cancer cells, in which both proteins are well expressed. In
support of our hypothesis, silencing ERRa expression signif-
icantly reduced OPN gene and protein expression in this cell
line. Other ERRa target genes have been proposed to
contribute to the malignant phenotype of cancer cell lines,
including vascular endothelial growth factor,34,53 osteoprote-
gerin, and the matrix metalloproteinases 1 and 1334 and
WNT11.43 Of interest, the regulation of OPN expression by
ERRa has mostly been investigated in the context of bone
biology. In particular, Bonnelye et al54 reported that either
siRNA-mediated silencing of ERRa or the expression of
a dominant-negative form of ERRa resulted in lower mouse
OPN levels in the RAW264.7 monocyte-macrophage cell line
that differentiates in osteoclasts. Furthermore, the character-
ization of the regulation of OPN expression by ERRa has been
mainly performed in cell lines of rodent origin.
In the present study, luciferase assays showed that the
ERRa/PGC-1a complex positively regulated the human
OPN promoter. In our hands, transient overexpression of
ERRa alone did not affect human OPN promoter activity,
likely because its transcriptional activity is strongly linked to
the availability of its co-activators, including PGC1a.26
Indeed, in addition to potentiating ERRa transcription
of its targets, including OPN, PGC1a can also increase
ERRa expression through a positive loop because its own-
promoter harbors three ERRa functional response
elements.27 PGC1a co-activates several other nuclear
receptors, including peroxisome proliferator-activated re-
ceptor g, ERa, glucocorticoid receptor, thyroid hormone
receptor, liver X receptor, retinoid X receptor a, and farne-
soid X receptor.55 The fact that the induction of OPN by the
ERRa/PGC-1a complex is strongly attenuated by pharma-
cologic or shRNA-mediated knockdown of ERRa supports
a speciﬁc role for ERRa in OPN transactivation. The role of
ERRa in colorectal tumor growth may therefore be mediated
in part by increased expression of OPN.
There is some controversy as to whether ERRa regulates
OPN expression in a cell- and species-dependent manner,
through either canonical or noncanonical response elements.24
The putative ERREs contain the core AGGTCA sequence
common to nuclear receptors, preceded by a TNA sequence,
in which N can be any nucleotide base.30 The present analysis
of the proximal human OPN promoter found three imper-
fect ERREs, named ERRE-S1 (TGACCTAGG), ERRE-S2
(CACAGGTCA), and ERRE-S3 (TAAAGGACA), in which
only the ﬁrst two harbor the core AGGTCA sequence (or
its reverse complement). This nuclear receptor half-site ap-
pears to be essential for ERRa/PGC-1a complex-mediated
transactivation because our mutation analysis showed that
disruption of this ERRE-S3 site did not affect hOPN
promoter-dependent luciferase activity. In turn, disruption of
either ERRE-S1 and/or ERRE-S2 sites resulted in attenuated
induction of hOPN activity, whereas mutation of the ERRE-2
sequence reduced basal hOPN activity, possibly related to the
presence of endogenous ERRa and PGC1a in HEK293T
cells. These two response elements are located 80 pairs apart,ajp.amjpathol.org - The American Journal of Pathology
ERRa and Osteopontin Expression in CRCsuggesting a possible coordination between these sites in the
activation of the OPN promoter by ERRa. Overall, our ﬁnd-
ings suggest that ERRa binds to the ERRE-S1 and ERRE-S2
sequence within the proximal promoter of human OPN and
that the ERRa/PGC-1a complex positively regulates its
activity.
Although relatively straightforward, conditions associated
with luciferase assay remain artiﬁcial and may not neces-
sarily reﬂect the in vivo cell-speciﬁc environment and native
chromatin structure. In fact, a recent study reported that the
activity of the OPN promoter can be repressed by Tri-
chostatin, a potent histone deacetylation, in HeLa cells.56
We therefore investigated whether ERRa occupies the
human OPN promoter in HT29 cells, using a validated ChIP
assay. Consistent with results from our luciferase assay, we
found that ERRa binds to the human OPN promoter in
a region containing the ERRE-S1 and ERRE-S2 sites. These
sites are however too close to accurately discriminate ERRa
binding of the ERRE-S1 versus the ERRE-S2 site. ERRa
could collaborate with transcription factors pertinent to CRC
biology to induce OPN expression. In particular, the hOPN
promoter has been reported to be activated by Wnt/b-
catenin/T-cell factor 418 involved in early stages of CRC.
Furthermore, cooperation between ERRa and b-catenin has
been shown to contribute to the expression of WNT11 factor
and to MDA-MB-231 breast cancer cell migration.43 Further
studies are required to fully understand the cross talk
between ERRa and CRC-enriched oncogenic factors as well
as the contribution of each of the latter in the regulation
of gene expression involved in CRC development and
progression.
In conclusion, with the use of TMA samples of CRC, our
results show that ERRa and OPN are co-expressed and
higher in tumor epithelial cells as opposed to normal mucosa.
Furthermore, our data provide compelling evidence that OPN
is a direct target of ERRa, the induction of which could
clearly contribute to CRC pathogenesis. These ﬁndings also
support the growing interest in developing ERRa antago-
nists as therapeutic options in cancer treatment.Acknowledgments
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